Brief: Vyne Therapeutics Announces Phase 1B Data For Treatment Of Mild-To-Moderate Atopic Dermatitis

YARROW BIOSCIENCE

19/01/2022 13:44

Jan 19 (Reuters) - Vyne Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS ANNOUNCES PHASE 1B DATA FOR FMX114 FROM
PHASE
1B/2A TRIAL FOR TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS
    * VYNE THERAPEUTICS INC - FINDINGS FROM PHASE 1B SAFETY
PORTION OF
STUDY SUPPORT TRIAL CONTINUATION
    * VYNE THERAPEUTICS INC - TOPLINE PHASE 2A RESULTS EXPECTED
IN Q1
2022
    * VYNE THERAPEUTICS- MEAN C OF TOFACITINIB 50-FOLD &
1500-FOLD
LOWER AT DAY 1 AND 14 OF STUDY COMPARED TO LOWEST COMMERCIALLY
AVAILABLE ORAL ALTERNATIVE
    * VYNE THERAPEUTICS- SYSTEMIC BIOAVAILABILITY OF TOFACITINIB
AND
FINGOLIMOD IN TOPICAL FORMULATION SUBSTANTIALLY LOWER COMPARED
TO ORAL EQUIVALENTS

Source text for Eikon:  ID:nGNX70551L 
Further company coverage:  VYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))